This includes the approval of maintenance therapy with the PARP inhibitor niraparib independent of the biomarker status [6], or the combined treatment with the PARP inhibitors olaparib and bevacizumab in BRCA1/2‐mutant or HRD‐positive ovarian cancer [9]. This evidence concerns the gene BRCA1 and ovarian carcinoma.